Investigation of TGFB1 −1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation

Petra Kövy,Nóra Meggyesi,Lívia Varga,Katalin Balassa,András Bors,László Gopcsa,Melinda Paksi,Árpád Bátai,Eszter Vad,János Sinkó,Attila Tordai,Tamás Masszi,Péter Reményi,Hajnalka Andrikovics

DOI: https://doi.org/10.1038/s41409-019-0656-4

2019-09-16

Bone Marrow Transplantation

Abstract:Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic option for malignant hematopoietic diseases. Cytokines including transforming growth factor β1 (TGFβ1) play a pivotal role in immune reconstruction, and the development of graft versus host disease (GvHD) or infections. The aim of this study was to investigate the role of <i>TGFB1</i> gene −1347C&gt;T variant in the outcome of HSCT in a cohort of 409 adult recipient-donor pairs. <i>TGFB1</i> variant was analysed from genomic DNA with LightCycler hybridisation probe method. In case of myeloablative conditioning, donor <i>TGFB1</i> genotype correlated with overall survival (60-month OS for CC: 62.1 ± 4.8%; CT: 46.8 ± 4.8%; TT: 35.6 ± 9.3%; <i>p</i> = 0.032), which was independent of age, donor type and GvHD prophylaxis in multivariate analysis (HR:2.35, 95%CI:1.35–4.10, <i>p</i> = 0.003). The cumulative incidence of acute GvHD grade III–IV [CC:10%; CT:17%; TT:24%], and non-relapse mortality was higher in TT-carriers (24-month NRM: CC:24%; CT:26%; TT:46%, <i>p</i> = 0.035). We did not find any association between recipient <i>TGFB1</i> −1347C&gt;T polymorphism and HSCT outcome. Our results suggest that donor <i>TGFB1</i> −1347C&gt;T may exert an adverse influence on the outcome of myeloablative conditioning transplantation.

oncology,immunology,hematology,transplantation